I will personally take it up with Brian in Melbourne in a few weeks time.
I hold because I'm long term. Yes we will instantly be in the money upon FDA approval and it will be downhill from there, but I'm also a realist this app is the first of its kind, I believe it will require extensive testing in the US before the FDA approve it.
I take from the 2 year research agreement alone signed with MGH that our app will not be approved whilst there may be some stones left unturned. It may be unapproved for those whole 2 years?
I'm no fan of the Motley fool but I can see where the writer is coming from in terms of commercialisation. FDA will not rush this app into hospitals.
More than happy to be proven wrong and be in the money 2nd half this year.
RAP Price at posting:
33.0¢ Sentiment: Buy Disclosure: Held